Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The brokerage currently has a $31.00 price target on the stock. Zacks Investment Research‘s target price points to a potential upside of 10.75% from the company’s current price.
According to Zacks, “Dova Pharmaceuticals, Inc. is a pharmaceutical company. It focuses on acquiring, developing and commercializing drug candidates for thrombocytopenia diseases. The company’s drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist which are in clinical stage. Dova Pharmaceuticals, Inc. is based in Durham, North Carolina. “
DOVA has been the subject of a number of other research reports. Jefferies Group LLC initiated coverage on Dova Pharmaceuticals in a report on Monday, July 24th. They issued a “buy” rating and a $30.00 target price for the company. Leerink Swann started coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They issued a “market perform” rating and a $24.00 price target on the stock. Finally, J P Morgan Chase & Co started coverage on shares of Dova Pharmaceuticals in a research note on Monday, July 24th. They issued an “overweight” rating and a $35.00 price target on the stock.
Dova Pharmaceuticals (NASDAQ:DOVA) last released its earnings results on Thursday, August 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.08). On average, analysts forecast that Dova Pharmaceuticals will post ($1.40) EPS for the current fiscal year.
In related news, Director Paul B. Manning purchased 25,870 shares of the company’s stock in a transaction dated Wednesday, August 16th. The shares were acquired at an average cost of $22.30 per share, with a total value of $576,901.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven M. Goldman purchased 20,169 shares of the company’s stock in a transaction dated Tuesday, August 15th. The stock was bought at an average cost of $22.23 per share, for a total transaction of $448,356.87. Following the completion of the purchase, the director now directly owns 81,158 shares of the company’s stock, valued at approximately $1,804,142.34. The disclosure for this purchase can be found here.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Paulson & CO. Inc. acquired a new position in shares of Dova Pharmaceuticals in the second quarter worth $13,856,000. Nexthera Capital LP acquired a new position in Dova Pharmaceuticals during the second quarter worth $4,415,000. Goldman Sachs Group Inc. acquired a new position in Dova Pharmaceuticals during the second quarter worth $493,000. Tudor Investment Corp ET AL acquired a new position in Dova Pharmaceuticals during the second quarter worth $699,000. Finally, FMR LLC acquired a new position in Dova Pharmaceuticals during the second quarter worth $43,969,000. 23.52% of the stock is currently owned by institutional investors and hedge funds.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
What are top analysts saying about Dova Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dova Pharmaceuticals Inc. and related companies.